Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

331 ARTÍCULOS , VIENDO DEL 226 AL 240

The APOE genotype: modification of therapeutic responses in Alzheimer's disease

Hanson AJ, Craft S, Banks WA.

Curr Pharm Des. 2015;21(1):114-20. doi: 10.2174/1381612820666141020164222.

Long-acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer's disease dementia

Claxton A, Baker LD, Hanson A, Trittschuh EH, Cholerton B, Morgan A, Callaghan M, Arbuckle M, Behl C, Craft S.

J Alzheimers Dis. 2015;44(3):897-906. doi: 10.3233/JAD-141791.

Vascular risk factors and Alzheimer's disease pathogenesis: are conventional pharmacological approaches protective for cognitive decline progression?

Safouris A, Psaltopoulou T, Sergentanis TN, Boutati E, Kapaki E, Tsivgoulis G.

CNS Neurol Disord Drug Targets. 2015;14(2):257-69. doi: 10.2174/1871527314666150217123147.

The selective positive allosteric M1 muscarinic receptor modulator PQCA attenuates learning and memory deficits in the Tg2576 Alzheimer's disease mouse model

Puri V, Wang X, Vardigan JD, Kuduk SD, Uslaner JM.

Behav Brain Res. 2015;287:96-9. doi: 10.1016/j.bbr.2015.03.029. Epub 2015 Mar 20.

Protection against Brain Atrophy by Anti-dementia Medication in Mild Cognitive Impairment and Alzheimer's Disease: Meta-Analysis of Longitudinal Randomized Placebo-Controlled Trials

Kishi T, Matsunaga S, Oya K, Ikuta T, Iwata N.

Int J Neuropsychopharmacol. 2015 Jun 19;18(12):pyv070. doi: 10.1093/ijnp/pyv070.

Advancements in the treatment of agitation in Alzheimer's disease

Antonsdottir IM, Smith J, Keltz M, Porsteinsson AP.

Expert Opin Pharmacother. 2015;16(11):1649-56. doi: 10.1517/14656566.2015.1059422.

Time to Response to Citalopram Treatment for Agitation in Alzheimer Disease

Weintraub D, Drye LT, Porsteinsson AP, Rosenberg PB, Pollock BG, Devanand DP, Frangakis C, Ismail Z, Marano C, Meinert CL, Mintzer JE, Munro CA, Pelton G, Rabins PV, Schneider LS, Shade DM, Yesavage J, Lyketsos CG; CitAD Research Group.

Am J Geriatr Psychiatry. 2015 Nov;23(11):1127-33. doi: 10.1016/j.jagp.2015.05.006. Epub 2015 May 19.

EFFECT OF EICOSAPENTAENOIC ACID AND DOCOSAHEXAENOIC ACID SUPPLEMENTATIONS TO CONTROL COGNITIVE DECLINE IN DEMENTIA AND ALZHEIMER'S DISEASE: A SYSTEMATIC REVIEW

de Souza Fernandes DP, Canaan Rezende FA, Pereira Rocha G, De Santis Filgueiras M, Silva Moreira PR, Gonçalves Alfenas Rde C.

Nutr Hosp. 2015 Aug 1;32(2):528-33. doi: 10.3305/nh.2015.32.2.9111.

Cannabinoids for the Treatment of Agitation and Aggression in Alzheimer's Disease

Liu CS, Chau SA, Ruthirakuhan M, Lanctôt KL, Herrmann N.

CNS Drugs. 2015 Aug;29(8):615-23. doi: 10.1007/s40263-015-0270-y.

Change in agitation in Alzheimer's disease in the placebo arm of a nine-week controlled trial

Rosenberg PB, Drye LT, Porsteinsson AP, Pollock BG, Devanand DP, Frangakis C, Ismail Z, Marano C, Meinert CL, Mintzer JE, Munro CA, Pelton G, Rabins PV, Schneider LS, Shade DM, Weintraub D, Newell J, Yesavage J, Lyketsos CG; CitAD Research Group.

Int Psychogeriatr. 2015 Dec;27(12):2059-67. doi: 10.1017/S1041610215001106. Epub 2015 Aug 25.

Interventions for Neuropsychiatric Symptoms in Neurocognitive Impairment Due to Alzheimer's Disease: A Review of the Literature

McClam TD, Marano CM, Rosenberg PB, Lyketsos CG.

Harv Rev Psychiatry. 2015 Sep-Oct;23(5):377-93. doi: 10.1097/HRP.0000000000000097.

Longitudinal Associations between Survival in Alzheimer's Disease and Cholinesterase Inhibitor Use, Progression, and Community-Based Services

Wattmo C, Londos E, Minthon L.

Dement Geriatr Cogn Disord. 2015;40(5-6):297-310. doi: 10.1159/000437050. Epub 2015 Sep 4.

Alzheimer's disease and language impairments: social intervention and medical treatment

Klimova B, Maresova P, Valis M, Hort J, Kuca K.

Clin Interv Aging. 2015 Aug 27;10:1401-7. doi: 10.2147/CIA.S89714. eCollection 2015.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias